Xerox Holdings Corporation Declares Dividend on Common and Preferred Stock

NORWALK, Conn.--(BUSINESS WIRE)-- Xerox Holdings Corporation (NASDAQ: XRX) announced today that its board of directors declared a quarterly dividend of $0.025 per share on Xerox Holdings Corporation Common Stock. The dividend is payable on October 30, 2026, to shareholders of record on September 30, 2026.

The board also declared a quarterly dividend of $20.00 per share on the outstanding Xerox Holdings Series A Convertible Perpetual Preferred Stock. The dividend is payable on October 1, 2026, to shareholders of record on September 15, 2026.

About Xerox Holdings Corporation (NASDAQ: XRX)

Xerox is a global technology company with more than 120 years of innovation leadership. We design, manufacture, deliver, and support print, IT, and digital services for nearly 200,000 clients worldwide. Our integrated, AI-powered portfolio includes managed and production print, document management, workflow automation, cybersecurity, cloud managed services, IT infrastructure, and collaboration technology. Serving clients from growing SMBs to 90 percent of the Fortune 500, Xerox supports leading healthcare, government, financial services, education, legal, retail, and commercial organizations. Through direct sales and a global network of channel partners, we deliver the technology, expertise, and support organizations need to operate efficiently, securely, and at scale.

Note: To receive RSS news feeds, visit www.news.xerox.com. For open commentary, industry perspectives and views, visit www.linkedin.com/company/xerox or www.youtube.com/XeroxCorp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260803113853/en/

Media Contact
Justin Capella, Xerox, [email protected]

Investor Contact
Greg Stein, Xerox, [email protected]

Source: Xerox Holdings Corporation

You May Also Be Interested In

• VIVEE Makes a Mysterious Debut as HTC Teases What’s Next
• IonQ and SDT Announce the First Strategic Partnership to Bring Both Advanced Quantum Computing and Quantum Networking to the Asia-Pacific Region
• Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026